# A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

> **NCT07107178** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Biotroy Therapeutics** · enrollment: 58 (estimated)

## Conditions studied

- Advanced Melanoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** BT02

## Key facts

- **NCT ID:** NCT07107178
- **Lead sponsor:** Biotroy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-08
- **Primary completion:** 2027-05
- **Final completion:** 2027-08
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107178, "A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07107178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*